Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Expected to Announce Quarterly Sales of $22.24 Million

Brokerages predict that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will post $22.24 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings. The lowest sales estimate is $20.75 million and the highest is $23.40 million. Adamas Pharmaceuticals posted sales of $18.79 million in the same quarter last year, which suggests a positive year over year growth rate of 18.4%. The firm is scheduled to issue its next quarterly earnings results on Thursday, August 5th.

On average, analysts expect that Adamas Pharmaceuticals will report full-year sales of $95.32 million for the current year, with estimates ranging from $88.06 million to $101.86 million. For the next year, analysts anticipate that the company will report sales of $124.94 million, with estimates ranging from $111.10 million to $149.76 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Sunday, May 9th. The specialty pharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.15. The business had revenue of $19.31 million for the quarter, compared to the consensus estimate of $19.59 million.

Several analysts recently weighed in on ADMS shares. SVB Leerink restated a “buy” rating and set a $6.00 price objective on shares of Adamas Pharmaceuticals in a research report on Thursday, May 13th. HC Wainwright raised their target price on Adamas Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday, June 7th. Finally, Zacks Investment Research raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research note on Monday, May 17th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Adamas Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $9.06.

In related news, insider Vijay Shreedhar sold 6,200 shares of Adamas Pharmaceuticals stock in a transaction on Monday, June 21st. The stock was sold at an average price of $5.16, for a total transaction of $31,992.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 18.90% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. The PNC Financial Services Group Inc. grew its position in shares of Adamas Pharmaceuticals by 42.9% in the first quarter. The PNC Financial Services Group Inc. now owns 10,000 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 3,000 shares in the last quarter. Walleye Capital LLC purchased a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $80,000. GSA Capital Partners LLP purchased a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $101,000. Zebra Capital Management LLC purchased a new position in shares of Adamas Pharmaceuticals during the 1st quarter worth approximately $112,000. Finally, Grantham Mayo Van Otterloo & Co. LLC purchased a new position in shares of Adamas Pharmaceuticals during the 1st quarter worth approximately $189,000. 69.82% of the stock is owned by institutional investors and hedge funds.

Shares of ADMS stock traded down $0.21 on Friday, hitting $5.37. 172,851 shares of the company’s stock were exchanged, compared to its average volume of 331,170. The company has a debt-to-equity ratio of 21.25, a quick ratio of 5.16 and a current ratio of 5.42. Adamas Pharmaceuticals has a 12 month low of $2.43 and a 12 month high of $9.15. The company has a market capitalization of $222.16 million, a PE ratio of -3.00 and a beta of 2.70. The stock’s 50 day moving average is $5.26.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.

Featured Story: How does a reverse stock split work?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.